Kwality Pharma Declares Q1 FY27 Unaudited Financial Results
Kwality Pharmaceuticals Ltd. announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company reported a strong start to FY27, with consolidated revenue growing 46% year-on-year to ₹162 crore and Profit After Tax (PAT) surging 119% year-on-year to ₹26 crore. Management has raised FY27 guidance across key metrics, including revenue to over ₹700 crore. The company also advanced its R&D programs, completing 13 Bioequivalence (BE) studies and securing 15+ new product registrations. Progress was also made on the biologics front with approval to initiate pre-clinical batches for Pembrolizumab.
Key Highlights
- Declared unaudited standalone and consolidated financial results for Q1 FY27.
- Consolidated revenue grew 46% YoY to ₹162 crore.
- PAT surged 119% YoY to ₹26 crore.
- Management raised FY27 revenue guidance to 700+ crore.
- Completed 13 BE studies and secured 15+ new product registrations.
Price Impact
More from KPL
Kwality Pharmaceuticals Closes Trading Window for Insider Trading
Kwality Pharma Q1FY27: consolidated PAT surges 115% YoY to ₹25.6 Cr, margins expand, guidance raised
Kwality Pharmaceuticals to hold 43rd AGM on August 31, 2026